

EXHIBIT I



US011141378B2

(12) **United States Patent**
Yaworski et al.

(10) **Patent No.:** **US 11,141,378 B2**
(45) **Date of Patent:** ***Oct. 12, 2021**

(54) **LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY**

(71) Applicant: **ARBUTUS BIOPHARMA CORPORATION, Vancouver (CA)**

(72) Inventors: **Edward Yaworski, Maple Ridge (CA); Kieu Lam, Surrey (CA); Lloyd Jeffs, Delta (CA); Lorne Palmer, Vancouver (CA); Ian MacLachlan, Mission (CA)**

(73) Assignee: **ARBUTUS BIOPHARMA CORPORATION, Vancouver (CA)**

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **17/227,802**

(22) Filed: **Apr. 12, 2021**

(65) **Prior Publication Data**
US 2021/0267895 A1 Sep. 2, 2021

Related U.S. Application Data

(63) Continuation of application No. 17/094,724, filed on Nov. 10, 2020, which is a continuation of application No. 16/422,441, filed on May 24, 2019, now abandoned, which is a continuation of application No. 15/840,933, filed on Dec. 13, 2017, now abandoned, which is a continuation of application No. 15/670,742, filed on Aug. 7, 2017, now abandoned, which is a continuation of application No. 15/164,803, filed on May 25, 2016, now abandoned, which is a continuation of application No. 14/462,441, filed on Aug. 18, 2014, now Pat. No. 9,364,435, which is a continuation of application No. 13/928,309, filed on Jun. 26, 2013, now Pat. No. 8,822,668, which is a continuation of application No. 13/253,917, filed on Oct. 5, 2011, now Pat. No. 8,492,359, which is a continuation of application No. 12/424,367, filed on Apr. 15, 2009, now Pat. No. 8,058,069.

(60) Provisional application No. 61/045,228, filed on Apr. 15, 2008.

(51) **Int. Cl.**
C07H 21/02 (2006.01)
C07H 21/04 (2006.01)
A61K 9/127 (2006.01)
A61K 48/00 (2006.01)
C07H 21/00 (2006.01)
C07J 9/00 (2006.01)
C12N 15/113 (2010.01)

(52) **U.S. Cl.**
CPC **A61K 9/1272** (2013.01); **A61K 9/1271** (2013.01); **A61K 31/713** (2013.01); **A61K 48/0025** (2013.01); **C07H 21/00** (2013.01); **C07J 9/00** (2013.01); **C12N 15/111** (2013.01); **C12N 15/113** (2013.01); **C12N 15/1137** (2013.01); **C12N 2310/14** (2013.01); **C12N 2320/32** (2013.01)

(58) **Field of Classification Search**
CPC C12N 15/113
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,394,448 A 7/1983 Szoka, Jr. et al.
4,438,052 A 3/1984 Weder et al.
4,515,736 A 5/1985 Deamer
4,598,051 A 7/1986 Papahadjopoulos et al.
4,897,355 A 1/1990 Eppstein et al.
5,013,556 A 5/1991 Woodle et al.
5,171,678 A 12/1992 Behr et al.
5,208,036 A 5/1993 Eppstein et al.
5,225,212 A 7/1993 Martin et al.
5,264,618 A 11/1993 Felgner et al.
5,279,833 A 1/1994 Rose
5,283,185 A 2/1994 Epanand et al.
5,320,906 A 6/1994 Eley et al.
5,334,761 A 8/1994 Gebeyehu et al.
5,545,412 A 8/1996 Eppstein et al.
5,578,475 A 11/1996 Jessee
5,627,159 A 5/1997 Shih et al.
5,641,662 A 6/1997 Debs et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2309727 A1 4/1999
CA 2271582 A1 11/1999

(Continued)

OTHER PUBLICATIONS

Basarkar et al. (Int J Nanomedicine, 2007, 2(3), 353-360).*

(Continued)

Primary Examiner — Amy H Bowman
(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend & Stockton LLP

(57) **ABSTRACT**

The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.

30 Claims. 24 Drawing Sheets

(56)

References Cited

U.S. PATENT DOCUMENTS

5,656,743	A	8/1997	Busch et al.	9,504,651	B2	11/2016	MacLachlan et al.
5,674,908	A	10/1997	Haces et al.	9,518,272	B2	12/2016	Yaworski et al.
5,703,055	A	12/1997	Felgner et al.	9,878,042	B2	1/2018	Yaworski et al.
5,705,385	A	1/1998	Bally et al.	10,053,689	B2	8/2018	Fitzgerald et al.
5,736,392	A	4/1998	Hawley-Nelson et al.	10,077,232	B2	9/2018	Heyes et al.
5,753,613	A	5/1998	Ansell et al.	10,415,037	B2	9/2019	Cross et al.
5,820,873	A	10/1998	Choi et al.	2001/0048940	A1	12/2001	Tousignant et al.
5,877,220	A	3/1999	Schwartz et al.	2003/0069173	A1	4/2003	Hawley-Nelson et al.
5,885,613	A	3/1999	Holland et al.	2003/0072794	A1	4/2003	Boulikas
5,958,901	A	9/1999	Dwyer et al.	2003/0077829	A1	4/2003	MacLachlan
5,976,567	A	11/1999	Wheeler et al.	2003/0143732	A1	7/2003	Fosnaugh et al.
5,981,501	A	11/1999	Wheeler et al.	2004/0063654	A1	4/2004	Davis et al.
6,020,202	A	2/2000	Jessee	2004/0142892	A1	7/2004	Finn et al.
6,020,526	A	2/2000	Schwartz et al.	2004/0253723	A1	12/2004	Tachas et al.
6,034,135	A	3/2000	Schwartz et al.	2004/0259247	A1	12/2004	Tuschi et al.
6,051,429	A	4/2000	Hawley-Nelson et al.	2005/0064595	A1	3/2005	MacLachlan et al.
6,075,012	A	6/2000	Gebeyehu et al.	2005/0118253	A1	6/2005	MacLachlan et al.
6,165,501	A	12/2000	Tirosh et al.	2005/0260757	A1	11/2005	Gebeyehu et al.
6,172,049	B1	1/2001	Dwyer et al.	2006/0008910	A1	1/2006	MacLachlan et al.
6,251,939	B1	6/2001	Schwartz et al.	2006/0134189	A1	6/2006	MacLachlan et al.
6,284,267	B1	9/2001	Aneja	2006/0147514	A1	7/2006	Gebeyehu et al.
6,287,591	B1	9/2001	Semple et al.	2006/0228406	A1	10/2006	Chiou et al.
6,339,173	B1	1/2002	Schwartz et al.	2006/0240093	A1	10/2006	MacLachlan et al.
6,376,248	B1	4/2002	Hawley-Nelson et al.	2006/0240554	A1	10/2006	Chen et al.
6,534,484	B1	3/2003	Wheeler et al.	2007/0042031	A1	2/2007	MacLachlan et al.
6,586,410	B1	7/2003	Wheeler et al.	2007/0135372	A1	6/2007	MacLachlan et al.
6,638,529	B2	10/2003	Schwartz et al.	2007/0202598	A1	8/2007	Chu et al.
6,649,780	B1	11/2003	Eibl et al.	2007/0202600	A1	8/2007	Chu et al.
6,671,393	B2	12/2003	Hays et al.	2008/0020058	A1	1/2008	Chen et al.
6,696,424	B1	2/2004	Wheeler et al.	2008/0317839	A1	12/2008	Quay et al.
6,815,432	B2	11/2004	Wheeler et al.	2009/0143583	A1	6/2009	Chu et al.
6,858,224	B2	2/2005	Wheeler et al.	2009/0291131	A1	11/2009	MacLachlan et al.
7,166,745	B1	1/2007	Chu et al.	2010/0130588	A1	5/2010	Yaworski et al.
7,422,902	B1	9/2008	Wheeler et al.	2010/0159593	A1	6/2010	Chu et al.
7,479,573	B2	1/2009	Chu et al.	2011/0076335	A1	3/2011	Yaworski et al.
7,491,409	B1	2/2009	Meers et al.	2012/0058188	A1	3/2012	MacLachlan et al.
7,601,872	B2	10/2009	Chu et al.	2012/0136073	A1	5/2012	Zhiwei et al.
7,687,070	B2	3/2010	Gebeyehu et al.	2012/0183581	A1	7/2012	Yaworski et al.
7,745,651	B2	6/2010	Heyes et al.	2012/0238747	A1	9/2012	Chu et al.
7,799,565	B2	9/2010	MacLachlan et al.	2013/0116307	A1	5/2013	Heyes et al.
7,803,397	B2	9/2010	Heyes et al.	2013/0122104	A1	5/2013	Yaworski et al.
7,807,815	B2	10/2010	MacLachlan et al.	2013/0303587	A1	11/2013	Yaworski et al.
7,838,658	B2	11/2010	MacLachlan et al.	2014/0065228	A1	3/2014	Yaworski et al.
7,901,708	B2	3/2011	MacLachlan et al.	2014/0294937	A1	10/2014	MacLachlan et al.
7,915,450	B2	3/2011	Chu et al.	2015/0164799	A1	6/2015	Yaworski et al.
7,939,505	B2	5/2011	Quay et al.	2015/0374834	A1	12/2015	Yaworski et al.
7,982,027	B2	7/2011	MacLachlan et al.	2016/0032320	A1	2/2016	Yaworski et al.
8,058,068	B2	11/2011	Hawley-Nelson et al.	2016/0251681	A1	9/2016	Yaworski et al.
8,058,069	B2	11/2011	Yaworski et al.	2017/0042814	A1	2/2017	Yaworski et al.
8,101,741	B2	1/2012	MacLachlan et al.	2017/0260523	A1	9/2017	Yaworski et al.
8,158,601	B2	4/2012	Chen et al.	2017/0307608	A1	10/2017	Bettencourt
8,158,827	B2	4/2012	Chu et al.	2018/0071397	A1	3/2018	Yaworski et al.
8,188,263	B2	5/2012	MacLachlan et al.	2018/0085312	A1	3/2018	Yaworski et al.
8,227,443	B2	7/2012	MacLachlan et al.	2018/0092848	A1	4/2018	Yaworski et al.
8,236,943	B2	8/2012	Lee et al.	2019/0032051	A1	1/2019	Yaworski et al.
8,283,333	B2	10/2012	Yaworski et al.	2019/0240339	A1	8/2019	Yaworski et al.
8,455,455	B1	6/2013	Robbins et al.	2020/0113832	A1	4/2020	Yaworski et al.
8,466,122	B2	6/2013	Heyes et al.	2021/0207140	A1	7/2021	Yaworski et al.
8,492,359	B2	7/2013	Yaworski et al.	2021/0220274	A1	7/2021	Yaworski et al.
8,513,403	B2	8/2013	MacLachlan et al.				
8,569,256	B2	10/2013	Heyes et al.				
8,598,333	B2	12/2013	MacLachlan et al.				
8,716,464	B2	5/2014	Geisbert et al.				
8,822,668	B2	9/2014	Yaworski et al.				
8,865,675	B2	10/2014	Heyes et al.				
8,999,950	B2	4/2015	MacLachlan et al.				
9,006,191	B2	4/2015	MacLachlan et al.				
9,006,417	B2	4/2015	Yaworski et al.				
9,018,187	B2	4/2015	Heyes et al.				
9,035,039	B2	5/2015	Dhillon et al.				
9,126,966	B2	9/2015	Martin et al.				
9,139,554	B2	9/2015	Hope et al.				
9,187,748	B2	11/2015	Geisbert et al.				

FOREIGN PATENT DOCUMENTS

CA	2330741	A1	11/1999	
CA	2397016	A1	7/2001	
CA	2513623		8/2004	
CA	2637931	*	7/2007 C12N 15/113
EP	1 648 519	B1	10/2014	
EP	2 567 693	B1	10/2015	
JP	03-126211		5/1991	
JP	05-202085		8/1993	
JP	06-080560		3/1994	
JP	2002-525063		8/2002	
JP	2003-505401		2/2003	
JP	2007-524349		8/2007	
WO	91/16024	A1	10/1991	
WO	93/05162	A1	3/1993	
WO	93/12240	A1	6/1993	

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	93/25673	A1	12/1993
WO	95/02698	A1	1/1995
WO	95/18863	A1	7/1995
WO	95/35301	A1	12/1995
WO	96/02655	A1	2/1996
WO	96/10390	A1	4/1996
WO	96/40964	A2	12/1996
WO	96/41873	A1	12/1996
WO	98/51285	A2	11/1998
WO	00/03683	A2	1/2000
WO	00/15820	A1	3/2000
WO	00/62813	A2	10/2000
WO	01/05374	A1	1/2001
WO	01/05873	A1	1/2001
WO	01/75164	A2	10/2001
WO	01/93836		12/2001
WO	02/034236	A2	5/2002
WO	02/087541	A1	11/2002
WO	03/097805	A2	11/2003
WO	2004/065546	A2	8/2004
WO	2004/110499	A1	12/2004
WO	2005/007196	A2	1/2005
WO	2005/026372	A1	3/2005
WO	2005/035764	A1	4/2005
WO	2005/120152	A2	12/2005
WO	2006/002538	A1	1/2006
WO	2006/053430	A1	5/2006
WO	2007/056861	A1	5/2007
WO	2009/086558	A1	7/2009
WO	2009/111658	A2	9/2009
WO	2010/042877	A1	4/2010
WO	2010/048228	A2	4/2010
WO	2010/088537	A2	8/2010
WO	2010/105209	A1	9/2010
WO	2013/090648	A1	6/2013
WO	2017/223135	A1	12/2017
WO	2018/232357	A1	12/2018

OTHER PUBLICATIONS

Shimada et al. (International Journal of Pharmaceutics, 203, 2000, 255-263).*

Gallie (Plant Cell Reports, 1993, 13, 119-122).*

Semple et al. (Biochemistry, 1996, 35, 2521-2525).*

Li et al. (Trends in Pharmacological Sciences, 23, 5, 2002, 206-209).*

Arima et al. (Biomaterials, 29, 2008, 551-560).*

Ahmad, A. et al., "New multivalent cationic lipids reveal bell curve for transfection efficiency versus membrane charge density: lipid-DNA complexes for gene delivery," J. Gene Med., 7(6):739-48, 2005.

Akinc, A. et al., "The Onpatro story and the clinical translation of nanomedicines containing nucleic acid-based drugs," Nature Nanotechnology, 14:1084-1087, 2019.

Alnylam Pharmaceuticals, Inc., ONPATRO Label, Revised Aug. 2018.

Ambebia, E. et al., "Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression," Biochimica et Biophysica Acta, 1669:155-163, 2005.

Arbutus Biopharma Corporation, "Arbutus' LNP Licensee Alnylam Announces FDA Approval of ONPATRO™ (patisiran), for the Treatment of ATTR Amyloidosis," Press Release, <https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-lnp-licensee-alnylam-announces-fda-approval-onpatrotm>, Aug. 13, 2018, 2 pages.

Arpicco, S. et al., "Preparation and characterization of novel cationic lipids developed for gene transfection," Proceed. Int'l Symp. Con-

Arpicco, S. et al., "Synthesis, characterization and transfection activity of new saturated and unsaturated cationic lipids," IL Farmaco, 59:869-878, 2004.

Bahl, K. et al., "Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses," Molecular Therapy, 25(6):1316-1327, 2017.

Ballas, N. et al., "Liposomes bearing a quaternary ammonium detergent as an efficient vehicle for functional transfer of TMV-RNA into plant protoplasts," Biochimica et Biophysica Acta, 939:8-18, 1988.

Barinaga, M., "Step taken toward improved vectors for gene transfer," Science, 266:1326, 1994.

Bass, B. "The short answer," Nature, 411:428-429, 2001.

Beale, G. et al., "Gene silencing nucleic acids designed by scanning arrays: Anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system," Journal of Drug Targeting, 11(7):449-456, 2003.

Behr, J., "Synthetic gene-transfer vectors," Acc. Chem. Res., 26:274-278, 1993.

Bennett et al., "Cholesterol enhances cationic liposome-mediated DNA transfection of human respiratory epithelial cells," Bioscience Reports, 15:47-53, 1995.

Brigham, K. et al., "Rapid communication: In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle," The American Journal of the Medical Sciences, 298(4):278-281, 1989.

Brummelkamp, T. et al., "A system for stable expression of short interfering RNAs in mammalian cells," Science, 296:550-553, 2002.

Cevc, G., "How membrane chain-melting phase-transition temperature is affected by the lipid chain asymmetry and degree of unsaturation: an effective chain-length model," Biochemistry, 30:7186-7193, 1991.

Check, E., "RNA to the Rescue? Disease therapies based on a technique for gene silencing called RNA interference are racing towards the clinic. Erika Check investigates molecular medicine's next big thing," Nature, 425:10-12, 2003.

Chonn, A. et al., "Recent advances in liposomal drug-delivery systems," Current Opinion in Biotechnology, 6:698-708, 1995.

Cortesi, R. et al., "Effect of cationic liposome composition on in vitro cytotoxicity and protective effect on carried DNA," International Journal of Pharmaceutics, 139:69-78, 1996.

Crystal, R., "Transfer of genes to humans: early lessons and obstacles to success," Science, 270:404-410, 1995.

Culver, K., "The first human gene therapy experiment," Gene Therapy: A Handbook for Physicians, 1994, pp. 33-40.

Duzgunes, N., "Membrane fusion," Subcellular Biochemistry, 11:195-286, 1985.

Dwarki, V. et al., "Cationic liposome-mediated RNA transfection," Methods in Enzymology, 217:644-654, 1993.

Elbashir, S. et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," Nature, 411:494-498, 2001.

Enoch, H. et al., "Formation and properties of 1000-Å-diameter, single-bilayer phospholipid vesicles," Proc. Natl. Acad. Sci. USA, 76(1):145-149, 1979.

European Medicines Agency, "New Medicine for Hereditary Rare Disease," Press Release, <https://www.ema.europa.eu/en/news/new-medicine-hereditary-rare-disease>, Jul. 27, 2018, 2 pages.

Felgner, J. et al., "Cationic lipid-mediated transfection in mammalian cells: 'Lipofection,'" J. Tiss. Cult. Meth., 15:63-68, 1993.

Felgner, J. et al., "Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations," The Journal of Biological Chemistry, 269(4):2550-2561, 1994.

Felgner, P. et al., "Cationic liposome mediated transfection," Proc. West. Pharmacol. Soc., 32:115-121, 1989.

Felgner, P. et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," Proc. Natl. Acad. Sci. USA, 84:7413-7417, 1987.

Filion, M.C. and Phillips, N.C., "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids towards

(56)

References Cited

OTHER PUBLICATIONS

- Gao, X. et al., "A novel cationic liposome reagent for efficient transfection of mammalian cells," *Biochem. Biophys. Res. Comm.*, 179(1):280-285, 1991.
- Gao, X. et al., "Nonviral gene Delivery: What we know and what is next," *AAPS Journal*, 9(1):E92-104, 2007.
- Gershon, H. et al., "Mode of formation and structural feature of DNA-cationic liposome complexes used for transfection," *Biochemistry*, 32:7143-7151, 1993.
- Global Newswire, retrieved from <http://globalnewswire.com> on Feb. 27, 2013, Tekmira sues Alnylam Pharmaceuticals for repeated misuse of trade secrets and confidential information, Mar. 16, 2011, pp. 1-3.
- Guy-Caffey, J. et al., "Novel polyaminolipids enhance the cellular uptake of oligonucleotides," *The Journal of Biological Chemistry*, 270(52):31391-31396, 1995.
- Hausseker, D., "The Business of RNAi Therapeutics in 2012," *Molecular Therapy-Nucleic Acids*, 2:e8, 2012, 12 pages.
- Hawley-Nelson, P. et al., "LipofectAmine™ reagent: a new, higher efficiency polycationic liposome transfection reagent," *Focus*, 15(3):73-80, 1993.
- Heyes, J. et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids," *Journal of Controlled Release*, 107:276-287, 2005.
- Heyes, J. et al., "Synthesis of novel cationic lipids: effect of structural modification on the efficiency of gene transfer," *J. Med. Chem.*, 45:99-114, 2002.
- Huang, L. et al., "Liposomal Gene Delivery: A Complex Package," *Nature Biotechnology*, 15:620-621, 1997.
- Hyde, S. et al., "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," *Nature*, 362:250-255, 1993.
- Janoff, A., "Declaration of Andrew S. Janoff, Ph.D. in support of Moderna Therapeutics, Inc.'s Petition for Inter Partes Review of U.S. Pat. No. 9,364,435," *Inter Partes Review of U.S. Pat. No. 9,364,435 B2*, Case No. IPR2018-00739, filed Mar. 5, 2018, 69 pages.
- Jiang, L. et al., "Comparison of protein precipitation methods for sample preparation prior to proteomic analysis," *Journal of Chromatography A*, 1023:317-320, 2004.
- Juliano, R. et al., "The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs," *Biochem. Biophys. Res. Commun.*, 63(3):651-658, 1975.
- Kauffman, K. et al., "Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs," *Nano Letters*, 15(11):7300-7306, 2015.
- Keough, K., "Influence of chain unsaturation and chain position on thermotropism and intermolecular interactions in membranes," *Biochem. Soc. Transactions*, 18(5):835-837, 1990.
- Krichevsky, A. et al., "RNAi functions in cultured mammalian neurons," *PNAS*, 99(18):11926-29, 2002.
- Lawrence, M. et al., "The formation, characterization and stability of non-ionic surfactant vesicles," *S.T.P. Pharma Sciences*, 6(1):49-60, 1996.
- Lawrence, M. et al., "Synthesis and aggregation properties of dialkyl polyoxyethylene glycerol ethers," *Chemistry and Physics of Lipids*, 82(2):89-100, 1996.
- Ledford, H., "Gene-Silencing Drug Approved: US Government Okays First RNA-Interference Drug—After a 20-Year Wait," *Nature*, 560:291-292, 2018.
- Legendre, J.-Y. et al., "Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes," *Pharm. Res.*, 9(10):1235-42, 1992.
- Leventis, R. et al., "Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles," *Biochem. Biophys. Acta*, 1023:124-132, 1990.
- Lin, A.J. et al., "Three-dimensional imaging of lipid gene-carriers: Membrane charge density controls universal transfection behavior in lamellar cationic liposome-DNA complexes," *Biophys. J.*, 84(5):3307-16, 2003.
- Liu, Y. et al., "Cationic liposome-mediated intravenous gene delivery," *J. Biol. Chem.*, 270:24864-70, 1995.
- MacLachlan, "Liposomal Formulations for Nucleic Acid Delivery," *Antisense Drug Technologies*, Second Edition; 2007; pp. 237-270.
- MacLachlan, I. and Cullis, P., "Diffusible-PEG-Lipid Stabilized Plasmid Lipid Particles," *Advances in Genetics*, 53:157-188, 2005.
- Marshall, E., "Gene therapy's growing pains," *Science*, 269:1050-1055, 1995.
- Middaugh, C. and Ramsey, C., "Analysis of Cationic-Lipid-Plasmid-DNA Complexes," *Analytical Chemistry*, American Chemical Society, 2007, pp. 7240-7248.
- Murahashi, N. et al., "Synthesis and application of neoglycolipid for liposome modification," *Biol. Pharm. Bull.*, 20(6):704-707, 1997.
- Orkin, S. et al., NIH Report, Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995, 41 pages.
- Ortho Biotech Products, LP, "Doxil® Label—Product Insert, Revised May 2007," https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050718s0291bl.pdf, 33 pages.
- Pak, C. et al., "Elastase-activated liposomal delivery to nucleated cells," *Biochimica et Biophysica Acta*, 1419:111-126, 1999.
- Parr, M. et al., "Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles," *Biochimica et Biophysica Acta*, 1195:21-30, 1994.
- Paul, C. et al., "Effective expression of small interfering RNA in human cells," *Nature Biotech.*, 20:505-508, 2002.
- Puyal, C. et al., "A new cationic liposome encapsulating genetic material: A potential delivery system for polynucleotides," *Eur. J. Biochem.*, 228:697-703, 1995.
- Sawada, K. et al., "Microemulsions in supercritical CO2 utilizing the polyethyleneglycol dialkylglycerol and their use for the solubilization of hydrophiles," *Dyes and Pigments*, 2005, 65:64-74.
- Schmidt, C., "Therapeutic Interference: Small RNA Molecules Act as Blockers of Disease Metabolism," *Modern Drug Discovery*, American Chemical Society, 2003, pp. 37-42.
- Sedic, M. et al., "Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey," *Veterinary Pathology*, 2017:1-14, 2017.
- Semple, S. et al., "Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid," *The Journal Of Pharmacology and Experimental Therapeutics*, 312(3):1020-1026, 2006.
- Semple, S. et al., "Rational Design of Cationic Lipids for siRNA Delivery," *Nature Biotechnology*, 28(2):172-176, 2010.
- Semple, S. et al., "Supplementary Text and Figures, Supplementary Fig. 1, Supplementary Tables 1-4 and Supplementary Syntheses 1 and 2 to Rational Design of Cationic Lipids for siRNA Delivery," *Nature Biotechnology*, 28(2):172-176, 2010, published online at <https://www.nature.com/articles/nbt.1602?draft=collection#supplementary-information>, last visited on Nov. 14, 2019, 19 pages.
- Shin, J. et al., "Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids," *Journal of Controlled Release*, 91:187-200, 2003.
- Song, L. et al., "Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes," *Biochimica et Biophysica Acta*, 1558:1-13, 2002.
- Sorensen, D. et al., "Gene silencing by systemic delivery of synthetic siRNAs in adult mice," *J. Biol. Chem.*, 327:761-766, 2003.
- Spagnou, S. et al., "Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA," *Biochemistry*, 43:13348-56, 2004.
- Stamatatos, L. et al., "Interactions of cationic lipid vesicles with

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.